Login to Your Account

Glybera Gains Official EMA Nod as First Gene Therapy

By Nuala Moran
Staff Writer

Wednesday, November 7, 2012
LONDON – Glybera formally became the first gene therapy to be approved in a regulated market, as the European Commission gave the rubber stamp to the treatment for the ultra-rare inherited disorder lipoprotein lipase deficiency (LPL) on Friday.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription